featured
Ibrutinib and Venetoclax as Primary Therapy in Symptomatic Patients With Treatment-Naïve MYD88-Mutated Waldenström Macroglobulinemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib and venetoclax as primary therapy in symptomatic treatment naïve Waldenström macroglobulinemia
Blood 2023 Oct 27;[EPub Ahead of Print], JJ Castillo, AR Branagan, D Sermer, C Flynn, KE Meid, M Little, K Stockman, TP White, AG Canning, ML Guerrera, A Kofides, S Liu, X Liu, K Richardson, N Tsakmaklis, CJ Patterson, ZR Hunter, SP Treon, S SarosiekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.